Nova Mentis Life Science Corp. (NOVA.CN)
CAD 0.01
(N/A%)
CAD 0.01
(N/A%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.2 Million CAD | -37.94% |
| 2022 | 1.93 Million CAD | -33.97% |
| 2021 | 2.93 Million CAD | 62.71% |
| 2020 | 1.8 Million CAD | 47.35% |
| 2019 | 1.22 Million CAD | -65.64% |
| 2018 | 3.56 Million CAD | 97.87% |
| 2017 | 1.79 Million CAD | -8.24% |
| 2016 | 1.96 Million CAD | 178.41% |
| 2015 | 704.54 Thousand CAD | 43.44% |
| 2014 | 491.18 Thousand CAD | 160.07% |
| 2013 | 188.86 Thousand CAD | -71.37% |
| 2012 | 659.68 Thousand CAD | -33.16% |
| 2011 | 986.92 Thousand CAD | 41.25% |
| 2010 | 698.69 Thousand CAD | -62.05% |
| 2009 | 1.84 Million CAD | 144.55% |
| 2008 | 752.79 Thousand CAD | 22.57% |
| 2007 | 614.19 Thousand CAD | 503.79% |
| 2006 | 101.72 Thousand CAD | 62.16% |
| 2005 | 62.72 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 90.17 Thousand CAD | -37.8% |
| 2024 Q1 | 144.98 Thousand CAD | -30.94% |
| 2023 Q2 | 302.05 Thousand CAD | -42.79% |
| 2023 Q1 | 528 Thousand CAD | 25.26% |
| 2023 Q4 | 209.93 Thousand CAD | -4.16% |
| 2023 Q3 | 219.03 Thousand CAD | -27.48% |
| 2023 FY | 1.25 Million CAD | -35.09% |
| 2022 Q4 | 421.53 Thousand CAD | -7.27% |
| 2022 FY | 1.93 Million CAD | -33.97% |
| 2022 Q1 | 662.11 Thousand CAD | 44.17% |
| 2022 Q2 | 399.03 Thousand CAD | -39.73% |
| 2022 Q3 | 454.58 Thousand CAD | 13.92% |
| 2021 Q4 | 459.27 Thousand CAD | -67.94% |
| 2021 FY | 2.93 Million CAD | 62.71% |
| 2021 Q3 | 1.43 Million CAD | 237.05% |
| 2021 Q2 | 424.97 Thousand CAD | -31.17% |
| 2021 Q1 | 617.44 Thousand CAD | -41.67% |
| 2020 Q4 | 1.05 Million CAD | 119.6% |
| 2020 Q1 | 141.33 Thousand CAD | 3.71% |
| 2020 FY | 1.8 Million CAD | 47.35% |
| 2020 Q2 | 121.31 Thousand CAD | -14.17% |
| 2020 Q3 | 482.03 Thousand CAD | 297.36% |
| 2019 Q3 | 391.47 Thousand CAD | 8.28% |
| 2019 Q2 | 361.52 Thousand CAD | 8.08% |
| 2019 Q1 | 334.49 Thousand CAD | -33.89% |
| 2019 Q4 | 136.28 Thousand CAD | -65.19% |
| 2019 FY | 1.22 Million CAD | -65.64% |
| 2018 Q2 | 232.68 Thousand CAD | -88.89% |
| 2018 Q3 | 710.08 Thousand CAD | 205.17% |
| 2018 FY | 3.56 Million CAD | 97.87% |
| 2018 Q1 | 2.09 Million CAD | 162.84% |
| 2018 Q4 | 506 Thousand CAD | -28.74% |
| 2017 Q3 | 402.13 Thousand CAD | 20.12% |
| 2017 FY | 1.79 Million CAD | -8.24% |
| 2017 Q2 | 334.78 Thousand CAD | 25.77% |
| 2017 Q1 | 266.18 Thousand CAD | -83.28% |
| 2017 Q4 | 796.62 Thousand CAD | 98.1% |
| 2016 Q3 | 194.05 Thousand CAD | 114.01% |
| 2016 Q1 | 85.19 Thousand CAD | -64.39% |
| 2016 FY | 1.96 Million CAD | 178.41% |
| 2016 Q2 | 90.67 Thousand CAD | 6.43% |
| 2016 Q4 | 1.59 Million CAD | 720.22% |
| 2015 FY | 704.54 Thousand CAD | 43.44% |
| 2015 Q1 | 169.11 Thousand CAD | 12.9% |
| 2015 Q2 | 115.74 Thousand CAD | -31.56% |
| 2015 Q3 | 180.43 Thousand CAD | 55.89% |
| 2015 Q4 | 239.25 Thousand CAD | 32.6% |
| 2014 Q1 | 72.51 Thousand CAD | 1223.33% |
| 2014 Q4 | 149.78 Thousand CAD | 13.9% |
| 2014 FY | 491.18 Thousand CAD | 160.07% |
| 2014 Q3 | 131.5 Thousand CAD | -4.27% |
| 2014 Q2 | 137.37 Thousand CAD | 89.46% |
| 2013 Q1 | 57.48 Thousand CAD | -61.32% |
| 2013 FY | 188.86 Thousand CAD | -71.37% |
| 2013 Q2 | 46.44 Thousand CAD | -19.21% |
| 2013 Q4 | -6455.00 CAD | -107.11% |
| 2013 Q3 | 90.82 Thousand CAD | 95.57% |
| 2012 Q1 | 161.78 Thousand CAD | -50.13% |
| 2012 FY | 659.68 Thousand CAD | -33.16% |
| 2012 Q3 | 211.27 Thousand CAD | 64.05% |
| 2012 Q4 | 148.6 Thousand CAD | -29.66% |
| 2012 Q2 | 128.78 Thousand CAD | -20.4% |
| 2011 Q2 | 284.73 Thousand CAD | 60.87% |
| 2011 Q1 | 177 Thousand CAD | 21.73% |
| 2011 Q3 | 200.78 Thousand CAD | -29.48% |
| 2011 FY | 986.92 Thousand CAD | 41.25% |
| 2011 Q4 | 324.4 Thousand CAD | 61.57% |
| 2010 Q3 | 149.47 Thousand CAD | -9.81% |
| 2010 Q1 | 238.08 Thousand CAD | -40.22% |
| 2010 Q4 | 145.4 Thousand CAD | -2.72% |
| 2010 Q2 | 165.73 Thousand CAD | -30.39% |
| 2010 FY | 698.69 Thousand CAD | -62.05% |
| 2009 Q4 | 398.24 Thousand CAD | -13.41% |
| 2009 FY | 1.84 Million CAD | 144.55% |
| 2009 Q3 | 459.9 Thousand CAD | 22.17% |
| 2009 Q2 | 376.45 Thousand CAD | -37.92% |
| 2009 Q1 | 606.39 Thousand CAD | 218.27% |
| 2008 Q2 | 188.09 Thousand CAD | 265.2% |
| 2008 Q3 | 322.67 Thousand CAD | 71.55% |
| 2008 FY | 752.79 Thousand CAD | 22.57% |
| 2008 Q1 | 51.5 Thousand CAD | -83.48% |
| 2008 Q4 | 190.52 Thousand CAD | -40.95% |
| 2007 Q4 | 311.79 Thousand CAD | 205.82% |
| 2007 Q1 | 100.13 Thousand CAD | 85.59% |
| 2007 Q3 | 101.95 Thousand CAD | 1.65% |
| 2007 Q2 | 100.29 Thousand CAD | 0.16% |
| 2007 FY | 614.19 Thousand CAD | 503.79% |
| 2006 Q3 | 17.34 Thousand CAD | 14.08% |
| 2006 FY | 101.72 Thousand CAD | 62.16% |
| 2006 Q1 | - CAD | 0.0% |
| 2006 Q4 | 53.95 Thousand CAD | 211.01% |
| 2006 Q2 | 15.2 Thousand CAD | 0.0% |
| 2005 FY | 62.72 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 5.19 Million CAD | 76.841% |
| Asep Medical Holdings Inc | 7.74 Million CAD | 84.471% |
| BetterLife Pharma Inc. | 3.24 Million CAD | 62.895% |
| BioVaxys Technology Corp. | 2.4 Million CAD | 49.958% |
| ChitogenX Inc. | 2.83 Million CAD | 57.516% |
| Rapid Dose Therapeutics Corp. | 4.2 Million CAD | 71.431% |
| Defence Therapeutics Inc. | 12.65 Million CAD | 90.5% |
| Entheon Biomedical Corp. | 564.31 Thousand CAD | -113.055% |
| Gemina Laboratories Ltd. | 5.08 Million CAD | 76.36% |
| Glow Lifetech Corp. | 25.71 Thousand CAD | -4575.477% |
| Lexston Life Sciences Corp. | 674.71 Thousand CAD | -78.193% |
| Pharmala Biotech Holdings Inc. | 1.21 Million CAD | 1.212% |
| Doseology Sciences Inc. | 72.08 Thousand CAD | -1567.844% |
| MYND Life Sciences Inc. | 1.47 Million CAD | 18.476% |
| PharmaTher Holdings Ltd. | 3.04 Million CAD | 60.504% |
| PreveCeutical Medical Inc. | 963.12 Thousand CAD | -24.833% |
| Telescope Innovations Corp. | 6.35 Million CAD | 81.073% |